Takeda and Alkermes Present OX2R Drug Findings for Narcolepsy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 08 2025
0mins
Source: Yahoo Finance
Takeda's OX2R Drug Results: Takeda presented positive Phase III trial results for its orexin receptor 2 (OX2R) drug, oveporexton, showing significant improvements in narcolepsy type 1 (NT1) symptoms, including Maintenance of Wakefulness Test scores and reductions in daytime sleepiness and cataplexy. The company plans to file for approval in 2025.
Alkermes' OX2R Drug Development: Alkermes reported data from its Phase II trial of alixorexton, an OX2R-selective agonist, which showed promising results but is still behind Takeda's drug in development. Alkermes aims to initiate a global Phase III program in early 2026, with a projected approval in 2028.
Analyst Views on ALKS
Wall Street analysts forecast ALKS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALKS is 46.17 USD with a low forecast of 37.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
11 Buy
3 Hold
0 Sell
Strong Buy
Current: 33.950
Low
37.00
Averages
46.17
High
58.00
Current: 33.950
Low
37.00
Averages
46.17
High
58.00
About ALKS
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
